ArticleInterdisciplinary cardiovascular and thoracic surgery2023
Durability of bioprosthetic aortic valve replacement in patients under the age of 60 years - 1-year follow-up from the prospective INDURE registry.
Article in Interdisciplinary cardiovascular and thoracic surgery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03666741 (Clinical Outcomes of Patients Under the Age of Sixty Undergoing INSPIRIS RESILIA Aortic Valve Replacement), which is not on this map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Outcomes of Patients Under the Age of Sixty Undergoing INSPIRIS RESILIA Aortic Valve Replacement
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.
- Early and late clinical outcomes and cost-effectiveness of aortic valve replacement using the Inspiris Resilia bioprosthesis : A systematic review and meta-analysis.Journal of cardiothoracic surgery · 2025Pooled it
- Hypo-attenuated leaflet thickening after surgical aortic valve replacement with INSPIRIS RESILIA valve.General thoracic and cardiovascular surgery · 2026Article
- Early Outcomes of Real-World Aortic Valve Replacement With RESILIA Tissue in the Chinese Population.Clinical cardiology · 2026Article
- Clinical Outcomes of a New-Generation Surgical Aortic Bioprosthesis: A Noninferiority Study.JTCVS open · 2026Article
- Three-Year Outcomes After Surgical Aortic Valve Replacement With a Bioprosthetic Valve from the Multi-Centre IMPACT Registry.Interdisciplinary cardiovascular and thoracic surgery · 2026Article
- Seven-Year Results for RESILIA Tissue in Bicuspid Aortic Valve Replacement Patients: Age and Valve Size Considerations.Interdisciplinary cardiovascular and thoracic surgery · 2025Article
- Sex-related differences in patient characteristics, practice patterns and outcomes after bioprosthetic and mechanical aortic valve replacement.Interdisciplinary cardiovascular and thoracic surgery · 2025Article
- A protocol of 'A post-market national POLish registry of biological prostheses with RESilia tissue (POLRES)'.Cardiology journal · 2025Article
- A "Watchful Surgery" Approach: Timing and Valve Choice for Mildly Symptomatic Mitral and Aortic Valve Disease.Journal of surgery and research · 2025Article
- Case Series of First Microinvasive Fully Endoscopic Use of a New Mitral Prosthesis.Journal of clinical medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 20 institutions in 10 countries.
Funding
Abstract
objectivesWe report 1-year safety and clinical outcomes in patients <60 years undergoing bioprosthetic surgical aortic valve intervention.
methodsThe INSPIRIS RESILIA Durability Registry is a prospective, multicentre registry to assess clinical outcomes of patients <60 years. Patients with planned SAVR with or without concomitant replacement of the ascending aorta and/or coronary bypass surgery were included. Time-related valve safety, haemodynamic performance and quality of life (QoL) at 1 year were assessed.
resultsA total of 421 patients were documented with a mean age of 53.5 years, 76.5% being male and 27.2% in NYHA class III/IV. Outcomes within 30 days included cardiovascular-related mortality (0.7%), time-related valve safety (VARC-2; 5.8%), thromboembolic events (1.7%), valve-related life-threatening bleeding (VARC-2; 4.3%) and permanent pacemaker implantation (3.8%). QoL was significantly increased at 6 months and sustained at 1 year. Freedom from all-cause mortality at 1 year was 98.3% (95% confidence interval 97.1; 99.6) and 81.8% were NYHA I versus 21.9% at baseline. No patient developed structural valve deterioration stage 3 (VARC-3). The mean aortic pressure gradient was 12.6 mmHg at 1 year and the effective orifice area was 1.9 cm2.
conclusionsThe 1-year data from the INSPIRIS RESILIA valve demonstrate good safety and excellent haemodynamic performance as well as an early QoL improvement. CLINICAL
trial registrationclinicaltrials.gov: NCT03666741.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.